After 15 months of planning, AbbVie has split away from Abbott, complete with a pipeline of more than 20 mid- and late-stage therapies, $18 billion in revenue and a commercial operation that spans the globe.
The termination of the BEACON study is a major setback for Abbott Laboratories, which had invested huge sums in bardoxolone and a second-generation portfolio that had been expected to provide its pharma spinout with blockbuster revenue.
Abbott ($ABT) has essentially doubled down on its high-stakes gamble that Reata Pharmaceuticals has the inside track on improving renal function in patients with chronic kidney disease, agreeing to
Abbott Labs' pharma-designated CEO, Richard Gonzalez, spent a good part of Friday painting a bright future for Abbott's proposed spinoff. Abbott, of course, already has a multibillion-dollar
Abbott Labs ($ABT) doesn't do a lot of deals compared with some of its Big Pharma rivals. But when the company inks a deal, it isn't afraid of using some big numbers. Abbott pledged $450 million just
Irving, TX-based Reata Pharmaceuticals snared a treasure trove of $450 million in upfront and near-term cash from Abbott Labs in exchange for the ex-U.S. licensing rights to the mid-stage chronic